



Supplementary Figure S1: Schema for intramyocardial injection of adenoassociated virus in mouse hearts. (a) The hair was removed by commercially available depilatory cream. (b) Sterilization of the operative site using several scrubs of povidone-iodine. (c) A sterile drape was employed to cover the operative site. (d) 0.5cm skin incision along the line connecting axilla and xiphoid. (e) Hearts were exposed through left thoracotomy at the 5th intercostal space with the help of forceps and a micro-mosquito hemostat. (f) AAV was delivered via direct injection into the left ventricular wall via Hamilton syringe (5 sites, 10 µl/site). (g-h) Closure of the skin and analgesic treatment.



Supplementary Figure S2: TRAF2 was upregulated in mouse hearts after sustained pressure overload. (a) CD147 possesses TRAF2-binding motif in its cytoplasmic domain. (b-c) Representative immunoblotting and statistical analysis of TRAF2 expression levels in cardiac tissue after TAC in indicated time points (n=3). *P < 0.05 vs the Sham group; **P < 0.01 vs the Sham group. (d) Correlation analysis between CD147 and TRAF2 protein expression levels in response to pressure overload in indicated time points (n=3).



Supplementary Figure S3: Blocking TAK1 activity reduced the downstream activation of CD147-mediated TRAF2-TAK1 signalling. (a-b) Representative western blots and quantitative results of the phosphorylated and total protein levels of TAK1, P38, P-JNK1/2 and Akt in hearts from vehicle and CD147-OE mice after TAC treated DMSO or 5Z-7-ox (n=4). *P < 0.05 vs the Vehicle group; ***P < 0.001 vs the Vehicle group; ***P < 0.001 vs the CD147-OE group; ###P < 0.001 vs the CD147-OE group; ####P < 0.001 vs the CD147-OE group.

Primer	Sequences
ANP	Forward:5'-
	CGTGCCCCGACCCACGCCAGCATGG -3'
	Reverse:5'-
	GCCTCCGAGGGCCAGCGAGCAGAGC -3'
BNP	Forward:5'- GAGGTCACTCCTATCCTCTGG -3'
	Reverse:5'- GCCATTTCCTCCGACTTTTCTC -3'
α-MHC	Forward:5'- TGCACTACGGAAACATGAAGTT -3'
	Reverse:5'- CGATGGAATAGTACACTTGCTGT -
	3'
β-ΜΗC	Forward:5'- ACTGTCAACACTAAGAGGGTCA -3'
	Reverse:5'- TTGGATGATTTGATCTTCCAGGG -3'
Collagen I	Forward:5'- GAGCGGAGAGTACTGGATCG -3'
	Reverse:5'- TACTCGAACGGGAATCCATC -3'
Collagen III	Forward:5'- CCATAGCTGAACTGAAAACCACC -
	3'
	Reverse:5'- CTGTAACATGGAAACTGGGGAAA -
	3'
MMP2	Forward:5'- CAAGTTCCCCGGCGATGTC -3'
	Reverse:5'- TTCTGGTCAAGGTCACCTGTC -3'
CTGF	Forward:5'- GGGCCTCTTCTGCGATTTC -3'
	Reverse:5'- ATCCAGGCAAGTGCATTGGTA -3'
GPX4	Forward:5'- GCCTGGATAAGTACAGGGGTT -3'
	Reverse:5'- CATGCAGATCGACTAGCTGAG -3'
NOX4	Forward:5'- GAAGGGGTTAAACACCTCTGC -3'
	Reverse:5'- ATGCTCTGCTTAAACACAATCCT -3'
FTH1	Forward:5'- CAAGTGCGCCAGAACTACCA -3'
	Reverse:5'- GCCACATCATCTCGGTCAAAA -3'
GAPDH	Forward:5'- GAGGTCACTCCTATCCTCTGG -3'
	Reverse:5'- GCCATTTCCTCCGACTTTTCTC -3'

Supplementary Table S1. Mouse primers sequences for qRT-PCR